Question · Q4 2025
Susan Anderson asked about the performance of Perrigo's core sales categories, seeking clarification on which categories are experiencing the most negative growth and which are performing better. She also inquired about the company's comfort with the current dividend level, its long-term leverage goals, and the strategic path for the infant nutrition business, including its historical earnings contribution and what would be required to make it accretive if retained.
Answer
President and CEO Patrick Lockwood-Taylor noted that preventative categories like VMS and certain digestive wellness subcategories are performing better, while cough, cold, and specific pain subsegments (e.g., pill dosing) are weaker, though topical creams and allergy are doing well. He reiterated unchanged capital allocation priorities: investing in the business, reducing leverage, and returning value to shareholders via dividends. CFO Eduardo Bezerra stated that 2026 net leverage is expected to be in line with or slightly better than 2025, with the long-term goal of below 3x now anticipated within 2-3 years due to transitory market effects. Regarding infant formula, Eduardo confirmed the strategic review is ongoing, assessing all options for optimizing P&L and cash flow. Patrick added that they expect low to mid-single digit revenue growth in infant formula for 2026 to clear lower-margin inventory, aiming to restore gross profit to 2024-2025 levels, with significant plant optimization opportunities for margin and cash flow expansion.
Ask follow-up questions
Fintool can predict
PRGO's earnings beat/miss a week before the call


